Polycystic ovary syndrome: a focus on anti-Müllerian hormone levels

References

• Franks S. Polycystic ovary syndrome. N. Engl. J. Med.333, 853–861 (1995).
   PubMed Web of Science ®Google Scholar
• Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin. Endocrinol. Metab.10, 221–247 (1996).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes38, 1165–1174 (1989).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care22, 141–146 (1999).
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for Type II diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab.84, 165–169 (1999).
   PubMed Web of Science ®Google Scholar
• O’Meara NM, Blackman JD, Ehrmann DA. Defects in β-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab.76, 1241–1247 (1993).
   PubMed Web of Science ®Google Scholar
• Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Polycystic Ovary Syndrome. Dunaif A, Givens JR, Haseltine F (Eds). Blackwell Scientific, MA, USA 377–384 (1992).
   Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod.19, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N. Engl. J. Med.352(12), 1223–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol.13, 946–957 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson VL, Qin KN, Rosenfield RL. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.86, 5925–5933 (2001).
   PubMed Web of Science ®Google Scholar
• Hughesdon PE. Morphology and morphogenesis of the Stein Leventhal ovary and of so-called ‘hyperthecosis’. Obstet. Gynecol. Surv.37, 59–77 (1982).
   PubMedGoogle Scholar
• Webber LJ, Stubbs S, Stark J et al. Formation and early development of follicles in the polycystic ovary. Lancet362, 1017–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum. Reprod. Update10(2), 107–117 (2004).
   PubMed Web of Science ®Google Scholar
• Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum. Reprod.18(3), 598–603 (2003).
   PubMed Web of Science ®Google Scholar
• Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr. Rev.17(2), 121–55 (1996).
   PubMed Web of Science ®Google Scholar
• Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update11(4), 357–374 (2005).
   PubMed Web of Science ®Google Scholar
• Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome – a hypothesis. J. Endocrinol.174(1), 1–5 (2002).
   PubMed Web of Science ®Google Scholar
• Steckler T, Wang J, Bartol F, Roy SK, Padmanabhan V. Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology46, 3185–3193 (2005).
   Google Scholar
• Cate RL, Mattaliano RJ, Heisson C, Tizard R, Farber NM, Cheung A. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell45, 685–698 (1986).
   PubMed Web of Science ®Google Scholar
• Josso N, di Clemente N. TGF-β family members and gonadal development. Trends Endocrinol. Metab.10, 216–222 (1999).
   Google Scholar
• Lee MM, Donahoe PK. Mullerian-inhibiting substance: a gonadal hormone with multiple functions. Endocr. Rev.14, 152–164 (1993).
   PubMed Web of Science ®Google Scholar
• Josso N, Cate RL, Picard JY et al. Anti-Mullerian hormone: the Jost factor. Recent Prog. Horm. Res.48, 1–59 (1993).
   PubMedGoogle Scholar
• Josso N, Lamarre I, Picard JY et al. Anti-Mullerian hormone in early human development. Early Hum. Dev.33, 91–99 (1993).
   PubMed Web of Science ®Google Scholar
• Josso N, Racine C, di Clemente N, Rey R, Xavier F. The role of anti-Mullerian hormone in gonadal development. Mol. Cell. Endocrinol.145, 3–7 (1998).
   PubMed Web of Science ®Google Scholar
• Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulose cells. J. Clin. Endocrinol. Metab.84, 3836–3844 (1999).
   PubMed Web of Science ®Google Scholar
• Cook CL, Siow Y, Taylor S, Fallat ME. Serum Mullerian-inhibiting substance levels during normal menstrual cycles. Fertil. Steril.73, 859–861 (2000).
   PubMed Web of Science ®Google Scholar
• Rey RA, Lhomme C, Marcillac I et al. Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum α-inhibin and estradiol. Am. J. Obstet. Gynecol.174, 958–965 (1996).
   PubMed Web of Science ®Google Scholar
• Lee MM, Donahoe PK, Hasegawa T et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J. Clin. Endocrinol. Metab.81, 571–576 (1996).
   PubMed Web of Science ®Google Scholar
• de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Anti-Mullerian hormone serum levels: a putative marker for ovarian aging. Fertil. Steril.77, 357–362 (2002).
   PubMed Web of Science ®Google Scholar
• Durlinger ALL, Gruijters MJ, Kramer P et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology143, 1076–1084 (2002).
   PubMed Web of Science ®Google Scholar
• Durlinger ALL, Gruijters MJ, Kramer P et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology142, 4891–4899 (2001).
   PubMed Web of Science ®Google Scholar
• di Clemente N, Goxe B, Remy JJ et al. Inhibitory effect of AMH upon aromatase activity and LH receptors of granulosa cells of rat and porcine immature ovaries. Endocrine2, 553–558 (1994).
   Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J. Clin. Endocrinol. Metab.88, 5957–5962 (2003).
   PubMed Web of Science ®Google Scholar
• Laven JS, Mulders AG, Visser JA, Themmen APN, DeJong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endocrinol. Metab.89, 318–323 (2004).
   PubMed Web of Science ®Google Scholar
• Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum. Reprod.20, 1820–1826 (2005).
   PubMed Web of Science ®Google Scholar
• Pellatt L, Hanna L, Brincat M et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J. Clin. Endocrinol. Metab.92(1), 240–245 (2007).
   PubMed Web of Science ®Google Scholar
• Stubbs SA, Hardy K, Da Silva-Buttkus P, et al. Anti-Mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J. Clin. Endocrinol. Metab.90(10), 5536–5543 (2005).
   PubMed Web of Science ®Google Scholar
• Rice S, Ojha K, Whitehead S, Mason H. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Mullerian hormone Type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries. J. Clin. Endocrinol. Metab.92(3), 1034–1040 (2007).
   PubMed Web of Science ®Google Scholar
• Lukas-Croisier C, Lasala C, Nicaud J et al. Follicle-stimulating hormone increases testicular anti-Mullerian hormone (AMH) production through sertoli cell proliferation and a nonclassical cyclic adenosine 5´-monophosphate-mediated activation of the AMH gene. Mol. Endocrinol.17(4), 550–561 (2003).
   PubMedGoogle Scholar
• Wachs DS, Coffler MS, Malcom PJ, Chang RJ. Serum anti-Mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J. Clin. Endocrinol. Metab.92(5), 1871–1874 (2007).
   PubMed Web of Science ®Google Scholar
• Catteau-Jonard S, Pigny P, Reyss AC, Decanter C, Poncelet E, Dewailly D. Changes in serum anti-Mullerian hormone level during low-dose recombinant follicular stimulating hormone therapy for anovulation in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. DOI: 10.1210/jc.2007-0868 (2007) (Epub ahead of print).
   Google Scholar
• Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol.134(2), 196–201 (2007).
   PubMed Web of Science ®Google Scholar
• Rey R, Lordereau-Richard I, Carel JC et al. Anti-Mullerian hormone and testosterone serum levels are inversely related during normal and precocious pubertal development. J. Clin. Endocrinol. Metab.77, 1220–1226 (1993).
   PubMedGoogle Scholar
• Al-Attar L, Noel K, Dutertre M et al. Hormonal and cellular regulation of Sertoli cell anti-Mullerian hormone production in the postnatal mouse. J. Clin. Invest.100(6), 1335–1343 (1997).
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Margalioth EJ, Gal M et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum. Reprod.20(7), 1814–1819 (2005).
   PubMed Web of Science ®Google Scholar
• Andersen CY, Lossl K. Increased intrafollicular androgen levels affect human granulosa cell secretion of anti-Mullerian hormone and inhibin-B. Fertil. Steril. DOI: 10.1016/j.fertnstert.2007.05.003 (2007) (Epub ahead of print).
   Google Scholar
• Crisosto N, Codner E, Maliqueo M et al. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.92(7), 2739–2743 (2007).
   PubMed Web of Science ®Google Scholar
• Kevenaar ME, Themmen AP, Laven JS et al. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum. Reprod.22(6), 1547–1554 (2007).
   PubMed Web of Science ®Google Scholar
• Kevenaar ME, Themmen AP, Rivadeneira F et al. A polymorphism in the AMH Type II receptor gene is associated with age at menopause in interaction with parity. Hum. Reprod.22(9), 2382–2388 (2007).
   PubMed Web of Science ®Google Scholar
• Tucci S, Futterweit W, Concepcion ES et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J. Clin. Endocrinol. Metab.86(1), 446–449 (2001).
   PubMed Web of Science ®Google Scholar
• Sir-Petermann T, Codner E, Maliqueo M et al. Increased anti-Mullerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.91(8), 3105–3109 (2006).
   PubMed Web of Science ®Google Scholar
• Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum. Reprod.17(10), 2573–2579 (2002).
   PubMed Web of Science ®Google Scholar
• Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW. Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol. Metab.9, 62–67 (1998).
   PubMed Web of Science ®Google Scholar
• Padmanabhan V, Evans N, Taylor JA, Robinson JE. Prenatal exposure to androgens leads to the development of cystic ovaries in the sheep. Biol. Reprod.56(Suppl. 1) 194 (1998).
   Google Scholar
• Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J. Clin. Endocrinol. Metab.91(3), 941–945 (2006).
   PubMed Web of Science ®Google Scholar
• La Marca A, Pati M, Orvieto R, Stabile G, Carducci Artenisio A, Volpe A. Serum anti-mullerian hormone levels in women with secondary amenorrhea. Fertil. Steril.85(5), 1547–1549 (2006).
   PubMed Web of Science ®Google Scholar
• Fleming R, Harborne L, MacLaughlin DT et al. Metformin reduces serum Müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil. Steril.83(1), 130–136 (2005).
   PubMedGoogle Scholar
• van Rooij IA, Broekmans FJ, te Velde ER et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod.17, 3065–3071 (2002).
   PubMed Web of Science ®Google Scholar
• Wang JG, Nakhuda GS, Guarnaccia MM, Sauer MV, Lobo RA. Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am. J. Obstet. Gynecol.196(1), 77.e1–e5 (2007).
   Web of Science ®Google Scholar
• van Rooij IA, Broekmans FJ, Scheffer GJ et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil. Steril.83, 979–987 (2005).
   PubMed Web of Science ®Google Scholar
• Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility Hum. Reprod.19(9), 2036–2042 (2004).
   PubMed Web of Science ®Google Scholar